Grant: Discovery Grants Program - Individual
University of British Columbia
$22,000.00
Mutasynthesis of asukamycin analogues
FY 2009-10
Summary
Fifty years ago, most people believed that we had successfully defeated all bacterial infections and that the cure
for cancer was just around the corner. In more recent times however, increasing numbers of infections and
tumours are showing resistance to the drugs that are most commonly used. This has started a race where we
work to discover new drugs faster than resistance can develop to the old ones. In this proposal I will study a
new way to generate drug candidates.
There are currently two traditional routes to finding bioactive molecules to use as drug candidates. The most
common method involves the extraction and purification of compounds from natural sources. Chemical
synthesis of novel compounds, or derivatives of natural products, is the second main source.
An alternative method that would result in the production of novel compounds would be by modification of
one or more biosynthetic genes involved in the production of an interesting structure to generate structural
analogues. Since the parent molecule has demonstrated bioactivity, the odds are greater for generating other
bioactive compounds by this method. Often the genes are already present in, or can be expressed in, an easily
culturable microorganism making the production of the compound inexpensive.
In this study, I propose to generate mutants in the asukamycin biosynthetic gene cluster from Streptomyces
nodosus spp asukaensis, rendering it unable to produce the starter unit to the "upper" portion of the molecule.
Feeding of analogues of this starter unit will result in the production of a variety of novel compounds to use in
drug screening assays. Asukamycin is an excellent candidate for a mutasynthesis study in that the CoA ligase
required for priming the polyketide synthase with the starter unit has been demonstrated to have low substrate
specificity. It has also been shown that the manumycin family of antibiotics, of which asukamycin is a
member, has a wide range of biological activities, including antimicrobial, antitumour, and antiinflammatory
responses.
Program
Discovery Grants Program - Individual
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
288143-2008
Name nom
Shipley, Paul
Department département
Okanagan - Chemistry & Earth and Environmental Science
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
22000
Program id
RGPIN
Program nane en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3705
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Bio-organic chemistry
Research subject fr
Chimie bio-organique
Partie
2
Nb partie
3
Application title
Mutasynthesis of asukamycin analogues
Keyword
NA
Application summary
Fifty years ago, most people believed that we had successfully defeated all bacterial infections and that the cure
for cancer was just around the corner. In more recent times however, increasing numbers of infections and
tumours are showing resistance to the drugs that are most commonly used. This has started a race where we
work to discover new drugs faster than resistance can develop to the old ones. In this proposal I will study a
new way to generate drug candidates.
There are currently two traditional routes to finding bioactive molecules to use as drug candidates. The most
common method involves the extraction and purification of compounds from natural sources. Chemical
synthesis of novel compounds, or derivatives of natural products, is the second main source.
An alternative method that would result in the production of novel compounds would be by modification of
one or more biosynthetic genes involved in the production of an interesting structure to generate structural
analogues. Since the parent molecule has demonstrated bioactivity, the odds are greater for generating other
bioactive compounds by this method. Often the genes are already present in, or can be expressed in, an easily
culturable microorganism making the production of the compound inexpensive.
In this study, I propose to generate mutants in the asukamycin biosynthetic gene cluster from Streptomyces
nodosus spp asukaensis, rendering it unable to produce the starter unit to the "upper" portion of the molecule.
Feeding of analogues of this starter unit will result in the production of a variety of novel compounds to use in
drug screening assays. Asukamycin is an excellent candidate for a mutasynthesis study in that the CoA ligase
required for priming the polyketide synthase with the starter unit has been demonstrated to have low substrate
specificity. It has also been shown that the manumycin family of antibiotics, of which asukamycin is a
member, has a wide range of biological activities, including antimicrobial, antitumour, and antiinflammatory
responses.